{
    "clinical_study": {
        "@rank": "94050", 
        "arm_group": [
            {
                "arm_group_label": "Patient: LGT209 50 mg", 
                "arm_group_type": "Experimental", 
                "description": "50 mg LGT209  subcutaneous (SC) (1 mL injection x 1 site) in statin patients"
            }, 
            {
                "arm_group_label": "Patient: LGT209 300 mg", 
                "arm_group_type": "Experimental", 
                "description": "300 mg LGT209  subcutaneous (SC) (1 mL injection x 2 sites) in statin patients"
            }, 
            {
                "arm_group_label": "Healthy Volunteers: LGT209 300 mg", 
                "arm_group_type": "Experimental", 
                "description": "300 mg LGT209 or placebo subcutaneous (SC) (1 mL injection x 2 sites) in healthy volunteers"
            }, 
            {
                "arm_group_label": "Patient: Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "matching placebo subcutaneous (SC) of LGT209 50 mg or 300 mg in statin patients"
            }, 
            {
                "arm_group_label": "Healthy volunteers: Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "matching placebo subcutaneous (SC) of LGT209 300 mg in healthy volunteers"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to investigate the safety, tolerability, pharmacokinetics  and\n      pharmacodynamics of LGT209 in hypercholesterolemic patients taking common statin medications\n      and in healthy volunteers."
        }, 
        "brief_title": "Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins", 
        "completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hypercholesterolemia,", 
            "LDL Cholesterol"
        ], 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy volunteers: Male and female subjects 18 to 70 years of age, in general good\n             health with fasting LDL-cholesterol >90 mg/dL and fasting serum triglycerides <400\n             mg/dL\n\n          -  Patients on statin therapy: Male and female patients 18 to 70 years of age receiving\n             atorvastatin or simvastatin and with fasting LDL-cholesterol >90 mg/dL and fasting\n             serum triglycerides <400 mg/dL\n\n        Exclusion Criteria:\n\n        Healthy volunteers:\n\n          -  History of hypersensitivity to any of the study drugs or to drugs of similar chemical\n             classes\n\n          -  Women of child-bearing potential unless using highly effective methods of\n             contraception\n\n          -  Conditions which might impact the safety or biologic activity of the study drug\n\n        Statin patients:\n\n          -  Use of concomitant medications known to impact the safe use or efficacy of\n             atorvastatin and simvastatin based on drug labels\n\n          -  Women of childbearing potential unless using highly effective methods of\n             contraception during dosing and for at least 100 days after study drug administration\n\n          -  Conditions which might impact the safety or biologic activity of the study drug\n\n        Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01859455", 
            "org_study_id": "CLGT209X2105"
        }, 
        "intervention": [
            {
                "arm_group_label": "Patient: LGT209 50 mg", 
                "description": "Active experimental drug", 
                "intervention_name": "LGT209 50 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Patient: LGT209 300 mg", 
                    "Healthy Volunteers: LGT209 300 mg"
                ], 
                "description": "Active experimental drug", 
                "intervention_name": "LGT209 300 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Patient: Placebo", 
                    "Healthy volunteers: Placebo"
                ], 
                "description": "Placebo comparator", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Patient: LGT209 50 mg", 
                    "Patient: LGT209 300 mg", 
                    "Patient: Placebo"
                ], 
                "description": "Stable doses of atorvastatin or simvastatin", 
                "intervention_name": "Statins (atorvastatin or simvastatin)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Atorvastatin", 
                    "Simvastatin"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Simvastatin", 
                "Atorvastatin", 
                "Hydroxymethylglutaryl-CoA Reductase Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hypercholesterolemia,", 
            "LDL cholesterol lowering,", 
            "proprotein convertase subtilisin/kexin type 9 (PCSK9),", 
            "LGT209,", 
            "drug safety,", 
            "pharmacokinetics,", 
            "pharmacodynamics"
        ], 
        "lastchanged_date": "May 17, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fort Myers", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33901-8144"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miramar", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33025"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Single Dose, Parallel Group Study to Assess the Safety, Tolerability, Bioavailability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous LGT209 in Hypercholesterolemic Patients on Stable Doses of Atorvastatin or Simvastatin and in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of subjects (patients and healthy volunteers) with adverse events, serious adverse events and death", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Plasma concentrations of LGT209 following subcutaneous administration", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) concentration", 
                "safety_issue": "No", 
                "time_frame": "baseline and 12 weeks"
            }, 
            {
                "measure": "Change from baseline in low density lipoprotein-cholesterol (LDL-C) concentration", 
                "safety_issue": "No", 
                "time_frame": "baseline and 12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01859455"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Plasma concentrations of atorvastatin in patients", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Plasma concentrations of simvastatin in patients", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Serum concentrations of PCSK9", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}